Fresenius SE & Co KGaA (FRA:FRE) Earns “Buy” Rating from DZ Bank

DZ Bank restated their buy rating on shares of Fresenius SE & Co KGaA (FRA:FRE) in a report released on Monday, Borsen Zeitung reports.

FRE has been the topic of a number of other reports. Kepler Capital Markets set a €62.00 ($72.09) price target on Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Friday, March 20th. Nord/LB set a €58.00 ($67.44) price objective on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Tuesday, February 25th. Credit Suisse Group set a €55.00 ($63.95) price objective on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Friday, February 21st. Berenberg Bank set a €72.10 ($83.84) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Monday, February 24th. Finally, Warburg Research set a €63.00 ($73.26) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Thursday, February 20th. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Fresenius SE & Co KGaA has an average rating of Buy and a consensus target price of €54.83 ($63.75).

Fresenius SE & Co KGaA stock opened at €34.47 ($40.08) on Monday. Fresenius SE & Co KGaA has a fifty-two week low of €60.16 ($69.95) and a fifty-two week high of €80.00 ($93.02). The firm has a 50 day moving average price of €41.16 and a 200 day moving average price of €45.61.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Recommended Story: Why are percentage gainers important?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.